Alkermes' Q3 Proprietary Sales Soar 18%
The biopharma company's third-quarter report highlighted robust proprietary product performance, despite some weakness ...
El Paso healthcare providers explore Vivitrol as a less known addiction treatment
Taking the first step to start addiction treatment is an uphill battle, but what can prove to be harder is keeping on a regimen that works.
Alkermes (NASDAQ:ALKS) Given New $43.00 Price Target at Cantor Fitzgerald
Alkermes (NASDAQ:ALKS – Free Report) had its price target lowered by Cantor Fitzgerald from $48.00 to $43.00 in a research ...
Nasdaq12d
Alkermes' Q3 Earnings & Revenues Fall Shy of Estimates, Stock Down
Alkermes plc ALKS reported adjusted earnings from continuing operations of 73 cents per share for third-quarter 2024, which missed the Zacks Consensus Estimate of 78 cents. The company had ...
Alkermes: Strong Buy Rating Amidst Short-term Challenges and Long-term Growth Potential
Robert W. Baird analyst Joel Beatty maintained a Buy rating on Alkermes (ALKS – Research Report) yesterday and set a price target of ...
Alkermes (NASDAQ:ALKS) Price Target Cut to $30.00
Alkermes (NASDAQ:ALKS – Get Free Report) had its target price dropped by equities researchers at The Goldman Sachs Group from ...
Alkermes Third Quarter 2024 Earnings: EPS Misses Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 2.9%. Looking ahead, revenue ...
Alkermes (ALKS) Receives a New Rating from Cantor Fitzgerald
In a report released yesterday, Charles Duncan from Cantor Fitzgerald initiated coverage with a Buy rating on Alkermes (ALKS – Research ...
PR Newswire13d
Alkermes plc Reports Third Quarter 2024 Financial Results
Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on ...